Abstract
Overview
Introduction
Osteoarthritis offers a very attractive commercial target in terms of patient
potential, and the explosion in new disease modifying drugs in rheumatoid
arthritis has highlighted the possibilities for OA. However, controversy in
the Cox-2 class, preconceptions about alternative treatments and even debate
around the definition of OA make this a more difficult market to break into
than first thought.
Scope
- Assessment of patient size across the seven major markets (US, Japan,
France, Germany, Italy, Spain, UK), including split by age and gender
- Transcripts based on qualitative interviews with key opinion leaders
including physicians, patient advocates and research scientists
- Investigation of the current unmet needs from a range of professionals
involved in osteoarthritis treatment and research
- Current treatment controversies and novel therapies in the developmental
pipeline
Report Highlights
High unmet need and a large patient population are key drivers towards
research and innovation in osteoarthritis. Datamonitor estimates that 89
million adults have some form of symptomatic osteoarthritis in the seven major
markets. However, ageist perceptions and low awareness provide a substantial
negative impact on the market.
Is a paradigm shift needed in the way osteoarthritis is treated? Treatment
currently centres on NSAIDs but in the light of recent controversies demand
for alternatives exists. Other effective treatment options are available, not
least changing lifestyle factors, but those that are currently available are
battling against their own preconceptions.
Clinical trials for disease modifying and symptomatic products for
osteoarthritis require careful design. However, the optimum design is not yet
decided among experts. Advances in imaging offer promise, but interpretation
of results must be unified and though the identification of biomarkers is
progressing, they are often difficult to utilize.
Reasons to Purchase
- Identify the challenges in disease modifying clinical trial design
including end-point selection
- Understand the key issues for alternative treatments propelled into the
treatment algorithm by the Cox-2 controversies
- Gain insight into opinion leaders' thoughts on the challenges facing the
osteoarthritis market
| 
View Cart
